Despite regulation changes in the Chinese healthcare industry, we think CSPC is well-positioned to maintain relatively strong revenue growth. First, generic drugs normally face the most severe price ...

The warehouse-club chain is taking steps to reduce its exposure to tariffs by pulling orders forward and moving sourcing of private-label products to the regions where they are sold. The storied ...

Stocks settled higher after an appeals court stayed an earlier decision to strike down President Trump's most sweeping tariffs while it considers the administration's challenge to it. If a court ...

China Resources Beverage is in sound financial shape thanks to its net cash position as of 2024 and solid margin profile. The company has generated over CNY 1 billion in operating cash flow annually ...

Target’s revenue declined 3.0% in the first quarter, underpinned by a 3.8% drop in comparable sales. Transaction count and ...

Steve Diggle's Artradis was once the biggest hedge fund in Asia. In the era of the global financial crisis and The Big Short, his tail-risk fund - a portfolio of instruments that benefit from highly ...

The continued decline in inflation means investors expect the ECB to cut borrowing costs by a quarter point next week to 2.0%. That would mark the eighth cut since June last year, when the rate was at ...

BP has appointed the former chief executive of U.S energy company Devon Energy, David Hager, as a nonexecutive director at a time when it is seeking to more than double its production of oil and gas ...

We assign MSC Industrial a Standard Capital Allocation Rating to reflect its sound balance sheet, mixed investments, and satisfactory shareholder distributions. MSC maintains conservative leverage and ...

Ray-Ban maker EssilorLuxottica said it would buy AI-focused ophthalmology platform Optegra from MidEuropa, as part of the group's medical technology strategy.

M&G said it formed a strategic partnership with Japanese insurance company Dai-ichi Life aimed at delivering at least $6 billion of new business flows for M&G over the next five years.

Sanofi and Regeneron said that drug candidate Itepekimab met the primary goal in one of two chronic obstructive pulmonary disease phase 3 studies, but didn't hit the main objective of a second trial.